| Literature DB >> 22457713 |
Walter Maetzler1, Martina Mancini, Inga Liepelt-Scarfone, Katharina Müller, Clemens Becker, Rob C van Lummel, Erik Ainsworth, Markus Hobert, Johannes Streffer, Daniela Berg, Lorenzo Chiari.
Abstract
BACKGROUND: The search for disease-modifying treatments for Parkinson's disease advances, however necessary markers for early detection of the disease are still lacking. There is compelling evidence that changes of postural stability occur at very early clinical stages of Parkinson's disease, making it tempting to speculate that changes in sway performance may even occur at a prodromal stage, and may have the potential to serve as a prodromal marker for the disease. METHODOLOGY/PRINCIPALEntities:
Mesh:
Year: 2012 PMID: 22457713 PMCID: PMC3311622 DOI: 10.1371/journal.pone.0032240
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic, clinical and sway parameters.
| PD | Individuals at high risk for PD | Controls | P-value | |
| Individuals (females) | 12 (5) | 20 (7) | 14 (7) | 0.71 |
| Age [ys] | 61.5 (2.2) | 61.9 (1.5) | 63.9 (1.9) | 0.53 |
| Weight [kg] | 79.3 (3.0) | 78.2 (2.3) | 72.6 (2.7) | 0.18 |
| Height [m] | 1.74 (0.02) | 1.73 (0.02) | 1.72 (0.02) | 0.80 |
| BMI [kg/m2] | 26.2 (0.8) | 25.9 (0.6) | 24.6 (0.7) | 0.24 |
| Age at disease onset [ys] | 57.9 (2.1) | |||
| Disease duration [ys] | 4.3 (2.6) | |||
| Hoehn&Yahr [1–5] | 2.0 (0.4) | |||
| UPDRS III [0–100] | 26.5 (10.9) | 3.3 (2.4) | 1.1 (1.7) | <0.0001 |
| MMSE [0–30] | 29.2 (1.0) | 29.2 (1.1) | 29.7 (0.5) | 0.23 |
| SN hyperechogenicity (cm2) | 0.24 (0.03) | 0.24 (0.03) | 0.14 (0.05) | <0.0001 |
| BDI [0–63] | 10.2 (8.5) | 5.9 (5.9) | 3.5 (3.7) | 0.02 |
| Pallaesthesia [0–8] | 7.3 (1.8) | 7.1 (1.4) | 7.9 (0.3) | 0.17 |
| ECF condition RMS ap (m/s2) | 0.19 (0.12) | 0.35 (0.17) | 0.17 (0.05) | 0.003 |
| ECF condition JERK ap (m2/s5) | 0.05 (0.04) | 0.30 (0.37) | 0.05 (0.04) | 0.01 |
| ECF condition RMS ml (m/s2) | 0.18 (0.08) | 0.28 (0.15) | 0.17 (0.05) | 0.03 |
| ECF condition JERK ml (m2/s5) | 0.13 (0.11) | 0.56 (0.62) | 0.09 (0.10) | 0.01 |
Data are presented with the mean and standard deviation. P-values were assessed by ANOVA with post-hoc Student's t test, or with the Pearson test.
p<0.017 compared to Parkinson's disease (PD),
p<0.017 compared to individuals at high risk for PD.
ap, anteroposterior; BDI, Beck's Depression Inventory; BMI, Body Mass Index; ECF, eyes closed with foam; ml, mediolateral; MMSE, Mini Mental State Examination; RMS, root mean square of sway; SN hyperechogenicity, mean area of hyperechogenicity of the substantia nigra; UPDRS III, motor part of the Unified Parkinson's disease Rating Scale.
Figure 1Root mean square acceleration and JERK results.
Root mean square acceleration and JERK in the anteroposterior direction, and mediolateral direction, of 12 patients with Parkinson's disease (PD), 20 individuals at increased risk for PD (HR-PD), and 14 controls when performing increasingly difficult sway tasks. Note the different scaling in some of the graphs.
Figure 2Traces of representative individuals.
Traces of the anteroposterior acceleration in the eyes open (EO), top, and eyes closed (EC), bottom, foam trials for a representative subject for each group: Parkinson's disease (PD) – dotted; increased risk for PD (HR-PD) – dashed; controls (CTR) – solid line.